Attitudes and beliefs about COPD: Data from the BREATHE study - 04/01/13
on behalf of the BREATHE Study GroupB
Summary |
Although COPD is a debilitating pulmonary condition, many studies have shown awareness of the disease to be low. This article presents data on attitudes and beliefs about COPD in subjects with respiratory symptoms participating in the BREATHE study in the Middle East and North Africa region. This study was a large general population survey of COPD conducted in ten countries of the region (Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Syria, Tunisia, Turkey and United Arab Emirates), together with Pakistan, using a standardised methodology. A total of 62,086 subjects were screened, of whom 2,187 fulfilled the “epidemiological” definition of COPD. A detailed questionnaire was administered to these subjects, which documented knowledge about the disease, attitudes to care, beliefs about COPD and satisfaction with treatment. 1,392 subjects were analysable. Overall, 58.6% of subjects claimed to be very well or adequately informed about their respiratory condition. Two-thirds of subjects reported receiving information about COPD from their physician and 10.6% from television; the internet was cited by 6% and other health professionals or patient associations by < 1%. Several inappropriate beliefs were identified, with 38.9% of respondents believing that there were no truly effective treatments, 73.7% believing that their respiratory condition would get progressively worse regardless of treatment and 29.6% being unsure what had caused their respiratory problems. Although 81% of respondents believed that smoking was the cause of most cases of COPD in general, only 51% accepted that it was the cause of their own respiratory problems. Treatment satisfaction was relatively high, with 83.2% of respondents somewhat or very satisfied with their physician’s management, in spite of the fact that only 47.5% considered that their physician’s advice had helped them manage their respiratory symptoms a lot. In conclusion, awareness of COPD in the region is suboptimal and treatment expectations are undervalued. Better patient education and more effective patient–physician communication are clearly required.
Le texte complet de cet article est disponible en PDF.Keywords : Perception, Attitudes, Beliefs, COPD, Middle East, North Africa, BREATHE study, Education, Treatment satisfaction
Plan
Conflict of interest statement AS, AA, NMO, MB, EU, SN, JAK and MAT have received honoraria from GlaxoSmithKline Laboratories for their contribution to the BREATHE study. MI has received honoraria from GlaxoSmithKline Laboratories for his contribution to the BREATHE study and has received speaking honoraria from AstraZeneca, Novartis, Sanofi, MSD, Pfizer, Actelion and Bayer. CN advised on the data management and statistical analysis of the results of the BREATHE study on behalf of GlaxoSmithKline Laboratories. NR and AEH are employees of GlaxoSmithKline Laboratories, which funded the BREATHE study and market a number of treatments for COPD. |
Vol 106 - N° S2
P. S60-S74 - décembre 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?